» Articles » PMID: 26519090

Urinary Kidney Injury Molecule-1 and Neutrophil Gelatinase-associated Lipocalin As Indicators of Tubular Damage in Normoalbuminuric Patients with Type 2 Diabetes

Overview
Journal Clin Biochem
Specialty Biochemistry
Date 2015 Nov 1
PMID 26519090
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Renal dysfunction has been reported in normoalbuminuric patients, demonstrating the necessity to improve the diagnostic and prognostic tools for diabetic kidney disease (DKD) investigation. Therefore, the aim of this study was to investigate whether the urinary levels of neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are increased in type 2 diabetes mellitus (DM) patients with normal or mildly increased albuminuria.

Design And Methods: In this study, 117 type 2 DM patients classified into three groups according to urinary albumin/creatinine ratio (uACR): uACR<10mg/g creatinine, uACR 10-30mg/g creatinine and uACR>30mg/g creatinine were enrolled. Urinary concentrations of KIM-1 (uKIM-1) and NGAL (uNGAL) were measured.

Results: uKIM-1 levels increased progressively from uACR<10mg/g creatinine (69.0±20.8pg/ml) to uACR 10-30mg/g creatinine (106.1±41.2pg/ml) and to uACR>30mg/g creatinine (166.0±31.9pg/ml) (P<0.001). In addition, uNGAL levels increased progressively from uACR<10mg/g creatinine (29.5±8.8ng/ml) to uACR 10-30mg/g creatinine (51.7±10.9ng/ml) and to uACR>30mg/g creatinine (71.0±9.6ng/ml) (P<0.001) patients. Similarly, both uKIM-1 and uNGAL adjusted by urinary creatinine were increased in patients with uACR 10-30mg/g creatinine. Significant and positive correlations were observed between uACR, uKIM-1 and uNGAL.

Conclusions: uKIM-1 and uNGAL were increased in type 2 DM patients with normal or mildly increased albuminuria, which indicates that tubular and glomerular injuries may be occurring even at the earliest stage of DKD.

Citing Articles

Changes in Urinary NGAL, FN, and LN Excretion in Type 2 Diabetic Patients Following Anti-Diabetic Therapy with Metformin.

Szeremeta A, Jura-Poltorak A, Grim A, Kuznik-Trocha K, Olczyk P, Ivanova D J Clin Med. 2025; 14(4).

PMID: 40004620 PMC: 11856773. DOI: 10.3390/jcm14041088.


Novel Insights into Diabetic Kidney Disease.

Mlynarska E, Bulawska D, Czarnik W, Hajdys J, Majchrowicz G, Prusinowski F Int J Mol Sci. 2024; 25(18).

PMID: 39337706 PMC: 11432709. DOI: 10.3390/ijms251810222.


Novel Biomarkers for the diagnosis of diabetic nephropathy.

Concepcion M, Quiroz J, Suarez J, Paz J, Roseboom P, Ildefonso S Caspian J Intern Med. 2024; 15(3):382-391.

PMID: 39011442 PMC: 11246682. DOI: 10.22088/cjim.15.3.382.


Identification of immune-associated biomarkers of diabetes nephropathy tubulointerstitial injury based on machine learning: a bioinformatics multi-chip integrated analysis.

Wang L, Su J, Liu Z, Ding S, Li Y, Hou B BioData Min. 2024; 17(1):20.

PMID: 38951833 PMC: 11218417. DOI: 10.1186/s13040-024-00369-x.


Phloretamide Protects against Diabetic Kidney Damage and Dysfunction in Diabetic Rats by Attenuating Hyperglycemia and Hyperlipidemia, Suppressing NF-κβ, and Upregulating Nrf2.

Al-Hussan R, Albadr N, Alshammari G, Almasri S, Alfayez F, Yahya M Pharmaceutics. 2024; 16(4).

PMID: 38675166 PMC: 11053512. DOI: 10.3390/pharmaceutics16040505.